| Size | Price | |
|---|---|---|
| Other Sizes |
| Targets |
H-Ala-OEt.HCl is not a pharmacological agent with a defined biological target. Its primary role is as a synthetic intermediate and building block in organic chemistry. The compound is used in the synthesis of nucleoside phosphoramidates as antiviral agents for human immunodeficiency and hepatitis B viruses. It is also used in the synthesis of enantiomerically pure amino acid ester isocyanates. The compound's utility is primarily in chemical synthesis rather than direct biological activity.
|
|---|---|
| ln Vitro |
Commercial ergot supplements have been made from amino acids and their derivatives. They affect the release of anabolic hormones, the availability of fuel for activity, the ability to think clearly under pressure, and the prevention of muscular damage brought on by exertion. They are regarded as advantageous synergistic food ingredients [1].
The in vitro activity of H-Ala-OEt.HCl is evaluated through its performance as a synthetic intermediate. It serves as a building block in peptide synthesis. The compound demonstrates high purity (>98.0%) and is used in the synthesis of various pharmaceutical compounds. Its reactivity is characterized by its ability to participate in peptide coupling reactions and other organic transformations. The compound's hydrochloride salt form enhances its solubility and stability. |
| ln Vivo |
In vivo activity is not applicable for H-Ala-OEt.HCl. The compound is not intended for administration to living organisms. It is exclusively a research chemical for laboratory synthesis.
|
| Enzyme Assay |
The in vitro enzyme/receptor binding (non-cellular) experimental workflow for H-Ala-OEt.HCl involves standard organic synthesis and peptide coupling procedures. A typical workflow: dissolve the compound in appropriate solvent, activate the carboxylic acid (if needed), and couple with other amino acid derivatives using standard coupling reagents. Characterize by NMR and MS. The compound is used in the synthesis of nucleoside phosphoramidates as antiviral agents and in the synthesis of enantiomerically pure amino acid ester isocyanates. The compound is available in various pack sizes.
|
| Cell Assay |
In vitro cell-based experimental workflows are not typically performed with H-Ala-OEt.HCl. The compound is not intended for biological activity screening. It is a synthetic intermediate used in medicinal chemistry workflows.
|
| Animal Protocol |
In vivo animal experiments are not applicable for H-Ala-OEt.HCl. The compound is stored as a solid at room temperature.
|
| ADME/Pharmacokinetics |
The pharmacokinetic properties of H-Ala-OEt.HCl have not been characterized. The compound is not a drug. No ADME data are available.
|
| Toxicity/Toxicokinetics |
The toxicological data for H-Ala-OEt.HCl are not well-documented. Standard laboratory safety practices should be followed. The compound is hygroscopic and should be handled accordingly. The compound is intended for research use only.
|
| References | |
| Additional Infomation |
H-Ala-OEt.HCl is a versatile compound frequently utilized in synthetic organic chemistry and biochemical research. It is used in the synthesis of nucleoside phosphoramidates as antiviral agents for human immunodeficiency and hepatitis B viruses. It is also used in the synthesis of enantiomerically pure amino acid ester isocyanates. The compound is available from multiple suppliers. It is not a drug and has no clinical trials or approvals. The compound is for research use only. The compound has synonyms including (S)-2-Aminopropionic Acid Ethyl Ester Hydrochloride and Ethyl (S)-2-Aminopropionate Hydrochloride. The compound has a molecular weight of 153.61 and a melting point of 77.0 to 83.0 °C.
|
| Molecular Formula |
C5H12CLNO2
|
|---|---|
| Molecular Weight |
153.61
|
| Exact Mass |
153.055
|
| CAS # |
1115-59-9
|
| PubChem CID |
2724356
|
| Appearance |
White to off-white solid powder
|
| Boiling Point |
127.8ºC at 760 mmHg
|
| Melting Point |
62ºC
|
| Flash Point |
3.5ºC
|
| Vapour Pressure |
11mmHg at 25°C
|
| LogP |
1.399
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
3
|
| Rotatable Bond Count |
3
|
| Heavy Atom Count |
9
|
| Complexity |
82.5
|
| Defined Atom Stereocenter Count |
1
|
| SMILES |
Cl[H].O(C([H])([H])C([H])([H])[H])C([C@]([H])(C([H])([H])[H])N([H])[H])=O
|
| InChi Key |
JCXLZWMDXJFOOI-WCCKRBBISA-N
|
| InChi Code |
InChI=1S/C5H11NO2.ClH/c1-3-8-5(7)4(2)6;/h4H,3,6H2,1-2H3;1H/t4-;/m0./s1
|
| Chemical Name |
ethyl (2S)-2-aminopropanoate;hydrochloride
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 6.5100 mL | 32.5500 mL | 65.0999 mL | |
| 5 mM | 1.3020 mL | 6.5100 mL | 13.0200 mL | |
| 10 mM | 0.6510 mL | 3.2550 mL | 6.5100 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
